* Blueprint Medicines Corp BPMC.OQ reported a quarterly
adjusted
loss of 89 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-2.20. The mean expectation of
nineteen analysts for the quarter was for a loss of 96 cents per
share. Wall Street expected results to range from $-1.12 to -71
cents per share.
* Revenue rose 126.6% to $128.18 million from a year ago;
analysts
expected $127.03 million.
* Blueprint Medicines Corp's reported EPS for the quarter
was a
loss of 89 cents.
* The company reported a quarterly loss of $56.28 million.
* Blueprint Medicines Corp shares had fallen by 9.8% this
quarter and lost 9.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 18.7%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Blueprint
Medicines Corp is 128.50
This summary was machine generated from LSEG data October 30 at
03:17 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.96 -0.89 Beat
Jun. 30 2024 -1.29 -0.80 Beat
Mar. 31 2024 -1.66 -1.32 Beat
Dec. 31 2023 -2.04 -1.82 Beat